Ovid Therapeutics
OVID
88 hedge funds and large institutions have $146M invested in Ovid Therapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 22 reducing their positions, and 16 closing their positions.
126% more capital invested
Capital invested by funds: $64.5M → $146M (+$81.2M)
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
18% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 22
11.63% more ownership
Funds ownership: 43.51% → 55.14% (+12%)
6% more funds holding
Funds holding: 83 → 88 (+5)
69% less call options, than puts
Call options by funds: $1.25M | Put options by funds: $4.02M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$20.2M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$8.25M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$6.3M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.74M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.35M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.89M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$2.21M |
| 4 |
CA
CHI Advisors
New York
|
-$1.93M |
| 5 |
Renaissance Technologies
New York
|
-$1.64M |
OVID Hedge Fund Activity: Q1 2021 in Review
88 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2021, worth a combined $146M — up 126% from $64.5M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new OVID positions and 16 closed out — a net gain of 6 holders — while 26 added to existing stakes and 22 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $20.2M. The largest seller was UBS Group, cutting an estimated $3.35M.
- 88 institutional investors held Ovid Therapeutics (OVID) as of Q1 2021, up from 83 in Q4 2020.
- Funds reported $146M of Ovid Therapeutics stock for Q1 2021, up 126% quarter-over-quarter.
- 22 funds opened new Ovid Therapeutics positions in Q1 2021 and 16 closed out, a net change of +6 holders.
- The largest Ovid Therapeutics buyer in Q1 2021 was EcoR1 Capital, an estimated $20.2M added.
- The largest Ovid Therapeutics seller in Q1 2021 was UBS Group, an estimated $3.35M sold.
Based on aggregated 13F filings for Q1 2021.